Is the 10x Genomics (TXG) CFO’s Form 4 sale a routine tax-related transaction?

Yes. The footnote explains the sale was made to cover tax withholding obligations linked to vesting restricted stock units. Such tax-driven sales are generally considered routine and tied to compensation events rather than signaling a change in sentiment.

10x Genomics CFO sells shares for tax withholding

10x Genomics, Inc. Chief Financial Officer Adam Taich reported a sale of company stock primarily to satisfy taxes from equity compensation.

Filing Impact

(High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

10x Genomics, Inc. Chief Financial Officer Adam Taich reported a sale of company stock primarily to satisfy taxes from equity compensation. On May 22, 2026, he sold 15,098 shares of Class A Common Stock at an average price of $24.4415 per share. According to the footnote, the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, making this a routine, compensation-driven transaction rather than a discretionary portfolio move. After the sale, Taich directly holds 379,898 shares of 10x Genomics Class A Common Stock.

Insider Trade Summary

Net Seller: 15,098 shares

Net Sell 1 txn

Insider Taich Adam

Role Chief Financial Officer

Sold 15,098 shs ($369K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	15,098	$24.4415	$369K

Holdings After Transaction: Class A Common Stock — 379,898 shares (Direct)

Footnotes (1)

F1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Key Figures

Shares sold: 15,098 shares Average sale price: $24.4415 per share Shares held after transaction: 379,898 shares

3 metrics

Shares sold 15,098 shares Open-market sale on May 22, 2026 to cover taxes

Average sale price $24.4415 per share Class A Common Stock transaction on May 22, 2026

Shares held after transaction 379,898 shares Direct holdings of CFO Adam Taich following Form 4 sale

Key Terms

restricted stock units, tax withholding obligations, open-market sale

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold to cover tax withholding obligations in connection with the vesting"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did 10x Genomics (TXG) report for Adam Taich?

10x Genomics reported that CFO Adam Taich sold 15,098 shares of Class A Common Stock. The transaction occurred on May 22, 2026 at an average price of $24.4415 per share, as disclosed in a Form 4 filing.

Why did 10x Genomics (TXG) CFO Adam Taich sell 15,098 shares?

The shares were sold to cover tax withholding obligations tied to vesting restricted stock units. This indicates a compensation-related, mechanistic sale rather than a discretionary decision to reduce his investment exposure to 10x Genomics stock.

How many 10x Genomics (TXG) shares does CFO Adam Taich hold after the sale?

After the reported transaction, CFO Adam Taich directly holds 379,898 shares of 10x Genomics Class A Common Stock. This remaining stake provides context that the 15,098 shares sold represent a relatively small portion of his total holdings.

What was the average price for the 10x Genomics (TXG) shares sold by the CFO?

The 15,098 shares of 10x Genomics Class A Common Stock were sold at an average price of $24.4415 per share. This per-share figure comes directly from the Form 4 transaction details for the May 22, 2026 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/27/2026 - 05:55 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taich Adam

(Last)

(First)

(Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON

CALIFORNIA

94588

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	05/22/2026		S⁽¹⁾		15,098	D	$24.4415	379,898	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Randy Wu, as Attorney-in-Fact for Adam Taich	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR